Last updated: September 13, 2026
HUMATE-P is a plasma-derived von Willebrand factor and factor VIII concentrate marketed by CSL Behring for von Willebrand disease and hemophilia A. Its commercial position rests on regulatory history, physician familiarity, specialized manufacturing, plasma supply, and treatment-center distribution rather than on recent patent exclusivity.
CSL does not publicly report standalone HUMATE-P revenue. The product is included within broader specialty and plasma-derived portfolios, so its financial trajectory must be assessed through product positioning, market competition, supply conditions, pricing, and the company’s segment disclosures rather than a separately disclosed sales series.
What is HUMATE-P and how does it work?
HUMATE-P contains human von Willebrand factor and coagulation factor VIII derived from pooled human plasma. It is administered intravenously and is used for:
- On-demand treatment and control of bleeding in adults and adolescents with von Willebrand disease.
- Perioperative management of bleeding in von Willebrand disease.
- Prevention and control of bleeding in adults and adolescents with hemophilia A.
The product’s dual-factor composition differentiates it from recombinant von Willebrand factor products that may require separate factor VIII administration during initial treatment in patients with low endogenous factor VIII levels.
| Attribute |
HUMATE-P |
| Active components |
Plasma-derived von Willebrand factor and factor VIII |
| Dosage form |
Intravenous lyophilized powder for reconstitution |
| Sponsor/marketer |
CSL Behring LLC |
| Manufacturing category |
Plasma-derived biologic |
| Main indications |
von Willebrand disease and hemophilia A |
| FDA pathway |
Biologics license application |
| Administration |
Intravenous |
| Primary customers |
Hematology centers, hospitals, specialty pharmacies, government purchasers |
| Regulatory exclusivity model |
Biologic exclusivity and patent rights, where applicable |
| Orange Book status |
Not generally listed as a conventional small-molecule drug |
| Biosimilar framework |
Purple Book and 351(k) pathway |
The FDA prescribing information identifies the product as a human plasma-derived coagulation factor concentrate and sets dosing by indication, target factor levels, body weight, and clinical circumstances. [1]
When did HUMATE-P receive FDA approval?
HUMATE-P has one of the longest commercial histories among plasma-derived von Willebrand factor products in the United States. Its historical FDA approval predates the modern biologics exclusivity framework created by the Biologics Price Competition and Innovation Act.
That timing limits the relevance of current statutory biologic exclusivity. Any original 12-year reference-product exclusivity period under the modern framework would have elapsed long ago. The commercial question is therefore not whether HUMATE-P retains regulatory exclusivity, but whether competitors can satisfy the technical, clinical, manufacturing, and supply requirements necessary to enter the market.
The product remains commercially relevant because approval of a competing coagulation-factor biologic does not automatically create pharmacy-level substitution. Hospitals and hemophilia treatment centers evaluate potency, viral safety, supply continuity, dosing protocols, reimbursement, and physician experience.
What patents protect HUMATE-P?
Publicly available regulatory and commercial materials do not identify a currently material, product-specific patent barrier that would prevent competition with HUMATE-P. The product’s core composition and manufacturing technology are based on long-established plasma fractionation methods.
Does HUMATE-P have Orange Book patents?
HUMATE-P is a biologic product rather than a conventional small-molecule drug. Biologic products generally are not managed through the same Orange Book patent-listing and Paragraph IV framework used for abbreviated new drug applications.
The FDA Orange Book is therefore not the primary source for HUMATE-P exclusivity analysis. Biologic reference-product status is tracked through the Purple Book, while patent disputes involving biologics can arise under the Biologics Price Competition and Innovation Act’s patent-exchange and litigation procedures. [2]
Are there formulation or method-of-use patents?
The relevant intellectual-property landscape may include historical patents covering:
- Plasma fractionation and purification.
- Viral inactivation.
- Stabilization and lyophilization.
- Factor VIII and von Willebrand factor compositions.
- Methods for treating bleeding disorders.
The commercial value of these rights is limited where patent terms have expired or where alternative manufacturing processes are available. HUMATE-P’s principal protection is operational rather than patent-based: access to qualified plasma, validated fractionation infrastructure, regulatory compliance, and a stable supply chain.
When does HUMATE-P lose exclusivity?
HUMATE-P has no meaningful remaining period of original regulatory exclusivity based on its long-established U.S. approval. The product’s current market protection is better described as mature biologic-market protection.
| Protection category |
Current relevance |
| Original product patent |
No publicly identified active patent appears to be the principal market barrier |
| Small-molecule Orange Book listing |
Generally not applicable |
| BLA reference-product exclusivity |
Historical period expired |
| Orphan-drug exclusivity |
Not the primary current protection mechanism |
| Manufacturing know-how |
Material |
| Plasma sourcing |
Material |
| Regulatory compliance |
Material |
| Switching and substitution barriers |
Material |
The absence of active core patent protection does not mean immediate generic-style entry. A competitor must develop a biologic manufacturing process, establish comparability or clinical efficacy as required by its regulatory pathway, qualify plasma or recombinant inputs, and maintain commercial supply.
Which companies compete with HUMATE-P?
HUMATE-P competes in two overlapping markets: von Willebrand factor replacement and factor VIII replacement.
Von Willebrand factor competitors
| Product |
Company |
Product type |
Competitive relevance |
| Wilate |
Octapharma |
Plasma-derived VWF/FVIII |
Direct dual-factor competitor |
| Vonvendi |
Takeda |
Recombinant VWF |
Direct VWF competitor; may require FVIII support in some patients |
| Alphanate |
Grifols |
Plasma-derived VWF/FVIII |
Competes in VWD and hemophilia A |
| Other factor concentrates |
Multiple manufacturers |
Plasma-derived or recombinant FVIII |
Compete primarily in hemophilia A |
Wilate is the closest direct commercial comparator because it also combines plasma-derived von Willebrand factor and factor VIII. Vonvendi competes through a recombinant product profile and a different factor VIII management strategy.
Hemophilia A competitors
HUMATE-P is exposed to competition from recombinant factor VIII products, extended-half-life factor VIII products, bypassing agents, and non-factor therapies. Hemlibra, marketed by Roche and developed with Chugai, has changed the hemophilia A treatment market by reducing reliance on routine factor VIII prophylaxis for many patients with and without inhibitors.
The effect is more significant in chronic hemophilia A prophylaxis than in acute bleeding or perioperative von Willebrand disease treatment. HUMATE-P’s VWD franchise gives it a separate demand base that is less directly exposed to hemophilia prophylaxis substitution.
How strong is the HUMATE-P patent estate?
The patent estate is weak as a current exclusivity instrument but the commercial franchise remains defensible.
Strengths
- Long clinical and physician experience.
- Established use in von Willebrand disease and hemophilia A.
- Dual VWF/FVIII composition.
- Existing treatment-center protocols.
- High technical barriers for plasma-derived manufacturing.
- Requirement for validated viral clearance and quality controls.
- Dependence on plasma collection and fractionation capacity.
Weaknesses
- No meaningful remaining original exclusivity period.
- Mature product technology.
- Direct competition from Wilate and other plasma-derived concentrates.
- Recombinant competition from Vonvendi.
- Non-factor therapies pressure the hemophilia A segment.
- Product-level revenue and growth are not separately disclosed by CSL.
HUMATE-P is therefore stronger as a supply-chain and brand franchise than as a patent-protected asset.
What is the FDA regulatory status of HUMATE-P?
HUMATE-P remains an FDA-approved biologic marketed under a biologics license. The FDA label covers dosing, contraindications, thromboembolic warnings, inhibitor development, hypersensitivity, and transmission-related risks associated with plasma-derived products. [1]
The product’s regulatory profile includes the following commercial implications:
- It has a mature safety record and established prescribing information.
- Plasma-derived status requires continued control of donor screening, viral testing, viral inactivation, and purification.
- The product cannot be treated as interchangeable with a competing VWF or factor VIII product solely because the products share a therapeutic category.
- Changes to manufacturing, facilities, specifications, or sourcing may require regulatory review.
Are there biosimilar or interchangeable versions of HUMATE-P?
No widely commercialized FDA-approved biosimilar or interchangeable product to HUMATE-P has established a routine substitution pathway comparable to generic substitution for small-molecule drugs.
A future 351(k) competitor would need to address the analytical and clinical complexity of a plasma-derived dual-protein product. The challenge is greater than demonstrating similarity for a single, well-characterized recombinant protein because plasma-derived products contain complex molecular distributions and functional attributes.
Competitive entry could instead occur through a standalone BLA or another biologics pathway rather than through a direct biosimilar substitution model. Such a product would still need to demonstrate adequate quality, safety, efficacy, and manufacturing control.
Which companies are challenging HUMATE-P exclusivity?
There is no prominent public Paragraph IV challenge to HUMATE-P comparable to a small-molecule ANDA patent dispute. That outcome follows from the product’s biologic status and the absence of a conventional Orange Book patent barrier.
Competition is occurring through product development and commercial positioning rather than a publicly visible patent challenge. The most relevant competitive companies include Octapharma, Takeda, Grifols, Roche, and manufacturers of recombinant and plasma-derived coagulation products.
What patent litigation affects HUMATE-P?
No major, currently active patent litigation involving HUMATE-P is broadly identified in the principal public regulatory and commercial sources. The practical legal risks are more likely to involve:
- Manufacturing and process patents held by competitors.
- Contract-manufacturing and supply agreements.
- Plasma procurement and licensing arrangements.
- Product-liability claims.
- Regulatory enforcement involving manufacturing quality.
- Trade-secret protection for fractionation and purification processes.
Because HUMATE-P is a mature biologic, litigation is less likely to focus on blocking generic entry through a single composition patent.
How does HUMATE-P compare with Wilate and Vonvendi?
| Factor |
HUMATE-P |
Wilate |
Vonvendi |
| VWF source |
Plasma-derived |
Plasma-derived |
Recombinant |
| FVIII included |
Yes |
Yes |
No routine fixed FVIII component |
| VWD use |
Yes |
Yes |
Yes |
| Hemophilia A use |
Yes |
Product labeling and market positioning differ by jurisdiction |
Not a direct FVIII replacement |
| Main differentiation |
Long market history and dual-factor use |
Direct plasma-derived competitor |
Recombinant technology |
| Supply risk |
Plasma and fractionation dependent |
Plasma and fractionation dependent |
Recombinant manufacturing dependent |
| Substitution |
Physician and protocol driven |
Physician and protocol driven |
Clinical-management dependent |
HUMATE-P’s strongest direct comparison is with Wilate. Vonvendi represents a technology-based alternative rather than a like-for-like dual-factor replacement.
What is the financial trajectory of HUMATE-P?
CSL does not disclose standalone HUMATE-P revenue, unit volume, gross margin, or product-level growth. Its financial contribution is reported within broader CSL Behring and plasma-derived specialty categories. [3]
The product’s likely financial trajectory has four phases:
| Period |
Market dynamic |
Financial implication |
| Early commercialization |
Limited competition and growing recognition of VWF replacement |
Market establishment |
| Mature franchise period |
Stable treatment-center use and recurring demand |
Durable revenue contribution |
| Current period |
Direct VWF competition, hemophilia innovation, and pricing pressure |
Low-growth or mixed trajectory |
| Forward period |
Stable VWD demand offset by competition and supply costs |
Cash-generative niche product with limited expansion |
Revenue drivers
- Incidence and diagnosis of von Willebrand disease.
- Perioperative use.
- Acute bleeding episodes.
- Hemophilia A treatment demand.
- Hospital and government procurement.
- Product availability.
- Plasma collection costs.
- Manufacturing yields.
- Reimbursement and contracting.
Revenue constraints
HUMATE-P is exposed to price pressure from direct plasma-derived competitors. It also faces a structural shift in hemophilia A toward extended-half-life products, prophylactic regimens, and non-factor therapies. That pressure is less pronounced in VWD, where replacement therapy remains dependent on factor-specific clinical needs.
The product is unlikely to be a major growth driver for CSL relative to high-growth plasma therapies, immunoglobulins, and newer specialty products. Its financial value is more consistent with a mature, recurring specialty franchise.
What generic launch risks exist for HUMATE-P?
A conventional generic launch scenario is unlikely because HUMATE-P is a biologic. The relevant risk is a competing biologic or follow-on product.
Low near-term risk
A near-term entrant would face:
- High development costs.
- Complex comparability requirements.
- Need for validated plasma or recombinant manufacturing.
- Limited substitution economics.
- Treatment-center and physician switching barriers.
- Supply and quality requirements.
- Small addressable market relative to development cost.
Medium-term risk
Risk increases if a competitor can offer:
- More predictable supply.
- A lower acquisition price.
- Higher VWF potency or a more convenient dosing profile.
- Recombinant production without plasma sourcing.
- Favorable reimbursement.
- Strong clinical data in perioperative VWD.
- A smaller infusion burden.
A successful entrant would probably take share gradually rather than produce an immediate, generic-style erosion event.
What manufacturing and intellectual-property barriers protect HUMATE-P?
The most important barriers are operational.
Plasma supply
Plasma-derived products depend on donor collection, testing, pooling, fractionation, and inventory management. Plasma shortages can increase costs and create allocation pressure across a manufacturer’s portfolio.
Viral safety
Manufacturers must operate validated systems for pathogen reduction and removal. These processes are subject to regulatory inspection and require consistent process performance.
Protein characterization
Von Willebrand factor is a complex multimeric protein. Product quality depends on functional activity, multimer distribution, factor VIII content, purity, stability, and consistency across lots.
Manufacturing scale
A competitor needs commercial-scale facilities, qualified personnel, validated equipment, and a reliable cold-chain and distribution network. These requirements reduce the probability of rapid market entry.
What geographic markets does HUMATE-P cover?
HUMATE-P is primarily associated with the U.S. market under the CSL Behring brand. CSL also markets related plasma-derived coagulation products internationally, although product names, indications, labeling, and market access can differ by country.
Geographic expansion is constrained by:
- National biologics approvals.
- Local reimbursement rules.
- Plasma-product procurement.
- Hospital tender systems.
- Treatment-center concentration.
- Country-specific safety and pharmacovigilance requirements.
The United States remains strategically important because of its specialized hemophilia-treatment network, commercial reimbursement system, and established use of factor concentrates.
Key Takeaways
- HUMATE-P is a mature plasma-derived VWF/FVIII biologic marketed by CSL Behring.
- Its principal indications are von Willebrand disease and hemophilia A.
- Original regulatory exclusivity and any foundational patent protection are no longer the primary commercial barriers.
- HUMATE-P is generally outside the conventional Orange Book and Paragraph IV framework.
- No prominent public biosimilar, generic, or active patent challenge has displaced the product.
- Wilate is the closest direct competitor; Vonvendi is the leading recombinant VWF comparator.
- The product’s financial trajectory is likely stable to modestly pressured, but CSL does not report standalone HUMATE-P revenue.
- Manufacturing complexity, plasma supply, viral-safety controls, and treatment-center familiarity provide more protection than patents.
- Hemophilia A innovation creates greater long-term pressure than the VWD market.
- A future entrant would likely produce gradual market-share erosion rather than an immediate generic cliff.
FAQs
Is HUMATE-P a factor VIII product?
Yes. HUMATE-P contains factor VIII and von Willebrand factor. It is used for hemophilia A and for selected von Willebrand disease treatment settings.
Is HUMATE-P recombinant or plasma-derived?
HUMATE-P is plasma-derived. It is manufactured from pooled human plasma and undergoes purification and viral-safety processing.
Can HUMATE-P be automatically substituted with Wilate?
Automatic substitution is generally not equivalent to generic substitution for a small-molecule drug. Selection depends on prescribing rules, institutional protocols, payer requirements, and physician judgment.
Does HUMATE-P have a biosimilar competitor?
No widely commercialized FDA-approved biosimilar or interchangeable product to HUMATE-P has established routine substitution in the U.S. market.
What is the largest commercial risk to HUMATE-P?
The largest risks are gradual share loss to Wilate and recombinant von Willebrand factor products, declining use in hemophilia A as non-factor therapies expand, and plasma-supply or manufacturing-cost pressure.
References
-
U.S. Food and Drug Administration. (2023). Humate-P prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
CSL Limited. (2024). Annual report 2024. CSL Limited.
